FREMONT, CA -- (Marketwire) -- 11/20/08 -- Cardima, Inc. (OTCBB: CADM) has engaged St. Louis-based Peerless Medical Inc. as the distributor for the Cardima Surgical Ablation System in the Midwestern United States, including the St. Louis, Kansas City, Wichita, Topeka and Omaha markets. Peerless, which enjoys strong relationships with leading cardiac surgeons in these territories, will market Cardima's Surgical Ablation System and solutions for cardiac patient care beginning immediately.

The Surgical Ablation System uses Cardima's patented technology for the ablation of cardiac tissue. The System incorporates a microcatheter-based surgical probe coupled with Cardima's INTELLITEMP®, a radiofrequency energy management device. The probe incorporates irrigation, suction and illumination, which aid in placement and lesion depth. The Cardima Surgical Ablation System is able to create deep, long, linear and transmural cardiac lesions without gaps. The small, flexible design offers sole port-hole access, potentially decreasing procedure time, patient hospital stay and discomfort.

"This agreement is another important step as we build a top distribution network in domestic and international markets for the Cardima Surgical Ablation System," said Cardima's CEO, Robert Cheney. "We look to leverage Peerless' strong relationships with leading cardiac surgeons, an invaluable asset in the medical industry, to help us build trust and goodwill for Cardima and our product lines. Peerless brings a seven-year track record of success selling to key physician groups and we look forward to working with them to make the Cardima Surgical Ablation System the number one choice of thoracic surgeons performing extensive linear ablation procedures."

Scott Chasin, Founder and Principal of Peerless Medical, said, "Our team at Peerless is impressed by the capabilities of the Cardima Surgical Ablation System. We see this System as an important new tool for cardiac surgeons who are increasingly seeking to perform complex 'open chest' and 'closed chest' ablation procedures with extensive linear lesion sets. We believe the Cardima system offers important benefits to the hospital, the physician and the patient. We look forward to working with Cardima to establish a major presence for the Surgical Ablation System in this sizeable and important market."

About Cardima

Cardima, Inc. has developed the PATHFINDER®, TRACER(TM) and REVELATION® Series of diagnostic catheters, the VUEPORT® and NAVIPORT® Series of guiding catheters, the INTELLITEMP® Energy Management Device and the Surgical Ablation System. All of these Cardima devices have received CE mark approval and U.S. Food and Drug Administration (FDA) 510(k) clearance. The REVELATION® Series of ablation catheters with the INTELLITEMP® EP Energy Management Device, developed for the treatment of atrial fibrillation (AF), has received CE mark approval and is marketed in Europe.

PATHFINDER®, TRACERTM, VUEPORT®, NAVIPORT®, REVELATION® and INTELLITEMP® are registered trademarks of Cardima, Inc.

For more information, please visit the Company's Web site at www.cardima.com.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements are subject to risks and uncertainties. Investors are referred to the full discussion of risks and uncertainties associated with forward-looking statements as contained in our reports to the Securities and Exchange Commission, including our Forms 10-K and 10-Q. The Company assumes no obligation to update the forward-looking information.